Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

Author:

Link-Gelles Ruth,Levy Matthew E.,Gaglani Manjusha,Irving Stephanie A.,Stockwell Melissa,Dascomb Kristin,DeSilva Malini B.,Reese Sarah E.,Liao I-Chia,Ong Toan C.,Grannis Shaun J.,McEvoy Charlene,Patel Palak,Klein Nicola P.,Hartmann Emily,Stenehjem Edward,Natarajan Karthik,Naleway Allison L.,Murthy Kempapura,Rao Suchitra,Dixon Brian E.,Kharbanda Anupam B.,Akinseye Akintunde,Dickerson Monica,Lewis Ned,Grisel Nancy,Han Jungmi,Barron Michelle A.,Fadel William F.,Dunne Margaret M.,Goddard Kristin,Arndorfer Julie,Konatham Deepika,Valvi Nimish R.,Currey J. C.,Fireman Bruce,Raiyani Chandni,Zerbo Ousseny,Sloan-Aagard Chantel,Ball Sarah W.,Thompson Mark G.,Tenforde Mark W.

Publisher

Centers for Disease Control MMWR Office

Subject

Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology

Reference10 articles.

1. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5.;Hachmann;N Engl J Med,2022

2. Protection against the Omicron variant from previous SARS-CoV-2 infection.;Altarawneh;N Engl J Med,2022

3. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.;Feikin;Lancet,2022

4. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes second booster dose of two COVID-19 vaccines for older and immunocompromised individuals. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-second-booster-dose-two-covid-19-vaccines-older-and

5. Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings.;Thompson;N Engl J Med,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3